RMD · Resmed Inc
Price
Snapshot
50 fields · last close| Market Cap | $33.61B |
| P/E | 22.06 |
| Float | 144.3M |
| Beta | 0.77 |
| Volatility | 19.2% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 78.9 |
| Price | 239.33 |
| Change | +0.15% |
| Prev Close | 238.97 |
| Open | 241.54 |
| Day Low | 237.87 |
| Day High | 242.57 |
| Avg Vol | 1 |
| Avg $ Vol | $271.2M |
| 52W High | 277.67 |
| 52W Low | 180.26 |
| 52W Pos | 60.6% |
| From High | −13.81% |
| From Low | +32.77% |
| Max DD 1Y | −33.75% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +5.66% |
| SMA 50 | +5.44% |
| SMA 200 | +6.35% |
| RSI (14) | 66.5 |
| Vol 30D | 21.9% |
| Vol 90D | 32.6% |
| 1Y Range | 180–278 |
| Daily bars | 536 |
| Perf Week | +3.88% |
| Perf Month | +4.62% |
| Perf Quarter | +20.32% |
| Perf Half Y | +4.76% |
| Perf Year | −11.39% |
| Perf YTD | −2.24% |
| Prev Day | +0.15% |
| Clavix | B+ |
| Debt / Eq | 0.06 |
| Curr Ratio | 3.10 |
| Int Cover | 58.2× |
| FCF Margin | 29.2% |
| Rev Growth | +9.8% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 21 / 49 |
What RMD does
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally.
The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution.
The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients’ device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system.
In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers.
ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Clavix risk grade
regraded every trading dayRMD grades B+, 78.9 of 100. Steadiest on News Sentiment (69), most exposed on Price Stability (62, mixed). 3 of the 4 weighted dimensions sit above the Health Care median. Ranks 21 of 49 in Health Care by Clavix score.
How rough the ride is
| RMD | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.77 | 0.84 |
| Volatilityannualized | 19.2% | 20.9% |
| Max drawdown, past yearworst peak-to-trough fall | −33.8% | — |
| Typical daily movemedian absolute daily change | 1.02% | — |
| Days beyond ±3%of the last 252 sessions | 22 (9%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| RMD | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.77 | 0.84 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate 53% of 49 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| RMD | |
|---|---|
| 1 week | +3.9% |
| 1 month | +4.6% |
| Year to date | −2.2% |
| 1 year | −11.4% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| RMD | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 6 Aug |
| Average score0 most bearish, 100 most bullish | 59 |
| Bullish · bearisharticles above 60 · below 40 | 16 · 6 |
| Directionarticles whose tone is improving vs worsening | 16 ↑ 6 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 49 Health Care names Clavix covers; the tick is the sector median.
Growth
| RMD | |
|---|---|
| Revenue growthyear over year | +9.8% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openResMed announced the U.S. launch of the AirTouch F40, a full-face fabric mask for its continuous positive airway pressure (CPAP) machines used to treat obstructive sleep apnea (OSA). The company says the new mask is designed to improve comfort and help users stay on their sleep apnea therapy over the long term.
ResMed CEO Michael Farrell sold 4,991 shares on October 7th at an average price of $226.33, totaling about $1.13 million, under a pre-arranged trading schedule (a Rule 10b5-1 plan, which is a pre-set buying or selling schedule insiders use so trades are not seen as based on non-public information). After the sale, Farrell still directly holds 479,803 shares worth roughly $108.6 million.
An opinion piece compares ResMed (RMD) and Stryker (SYK) as two ways to invest in medical device growth, noting both have grown sales about 10% a year on average over the past three years. It observes that Stryker trades at 32.6 times its past year's earnings versus 21.9 times for ResMed, and poses whether Stryker's larger size and broader hospital product range justify the higher price.
ResMed told investors at a Morgan Stanley conference it is targeting 12%-14% annual earnings-per-share growth, with executives pointing to rising demand for its sleep therapy equipment from patients taking GLP-1 weight-loss drugs, and emphasizing patient adherence and product innovation in sleep and respiratory care.
ResMed told investors at a Morgan Stanley conference that it is targeting 12%-14% annual earnings per share growth, and said rising demand for sleep therapy is being helped by patients using GLP-1 weight-loss drugs. Executives also highlighted plans to grow demand, keep patients using their devices and roll out new sleep and respiratory care products.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| CNC | Centene Corp | B | $34.16B | — | 1.08 | Compare |
| DXCM | Dexcom Inc | B | $32.47B | 32.48 | 1.44 | Compare |
| GEHC | GE Healthcare Technologies Inc | B | $31.42B | 15.83 | 0.83 | Compare |
| ALC | Alcon AG | B+ | $27.54B | 40.81 | 1.07 | Compare |
| DGX | Quest Diagnostics Inc | A- | $25.94B | 24.42 | 0.56 | Compare |
| LH | Labcorp Holdings Inc | A- | $25.79B | 25.73 | 0.89 | Compare |
| IDXX | IDEXX Laboratories Inc | B+ | $44.15B | 38.74 | 1.55 | Compare |
| MDLN | Medline Inc | B | $47.28B | 68.22 | 0.95 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.